nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—XDH—Carboplatin—testicular cancer	0.123	0.207	CbGbCtD
Carvedilol—XDH—Cisplatin—testicular cancer	0.105	0.177	CbGbCtD
Carvedilol—XDH—Doxorubicin—testicular cancer	0.0702	0.119	CbGbCtD
Carvedilol—PTGS1—Ifosfamide—testicular cancer	0.0628	0.106	CbGbCtD
Carvedilol—PTGS1—Etoposide—testicular cancer	0.03	0.0507	CbGbCtD
Carvedilol—GJA1—seminiferous tubule of testis—testicular cancer	0.0275	0.168	CbGeAlD
Carvedilol—CYP2C9—Ifosfamide—testicular cancer	0.0253	0.0427	CbGbCtD
Carvedilol—CYP2E1—Etoposide—testicular cancer	0.0232	0.0392	CbGbCtD
Carvedilol—ADRA1B—vas deferens—testicular cancer	0.0225	0.137	CbGeAlD
Carvedilol—SELE—vein—testicular cancer	0.0211	0.129	CbGeAlD
Carvedilol—ABCB1—Dactinomycin—testicular cancer	0.0208	0.0351	CbGbCtD
Carvedilol—VCAM1—vein—testicular cancer	0.0194	0.119	CbGeAlD
Carvedilol—CYP3A4—Ifosfamide—testicular cancer	0.0147	0.0248	CbGbCtD
Carvedilol—CYP1A2—Etoposide—testicular cancer	0.0134	0.0227	CbGbCtD
Carvedilol—ABCB1—Vinblastine—testicular cancer	0.013	0.022	CbGbCtD
Carvedilol—CYP2C9—Cisplatin—testicular cancer	0.0123	0.0208	CbGbCtD
Carvedilol—CYP2D6—Vinblastine—testicular cancer	0.0123	0.0207	CbGbCtD
Carvedilol—ABCB1—Cisplatin—testicular cancer	0.0119	0.0202	CbGbCtD
Carvedilol—ABCB1—Etoposide—testicular cancer	0.0117	0.0198	CbGbCtD
Carvedilol—ABCB1—Doxorubicin—testicular cancer	0.008	0.0135	CbGbCtD
Carvedilol—CYP3A4—Vinblastine—testicular cancer	0.0078	0.0132	CbGbCtD
Carvedilol—ABCB1—Methotrexate—testicular cancer	0.00775	0.0131	CbGbCtD
Carvedilol—CYP2D6—Doxorubicin—testicular cancer	0.00753	0.0127	CbGbCtD
Carvedilol—CYP3A4—Etoposide—testicular cancer	0.00702	0.0119	CbGbCtD
Carvedilol—CYP3A4—Doxorubicin—testicular cancer	0.00479	0.0081	CbGbCtD
Carvedilol—SELE—seminal vesicle—testicular cancer	0.00376	0.0229	CbGeAlD
Carvedilol—GJA1—Vinorelbine—Vinblastine—testicular cancer	0.00367	1	CbGdCrCtD
Carvedilol—HIF1A—embryo—testicular cancer	0.00354	0.0216	CbGeAlD
Carvedilol—VCAM1—seminal vesicle—testicular cancer	0.00345	0.0211	CbGeAlD
Carvedilol—GJA1—embryo—testicular cancer	0.00343	0.021	CbGeAlD
Carvedilol—HIF1A—seminal vesicle—testicular cancer	0.00332	0.0203	CbGeAlD
Carvedilol—GJA1—seminal vesicle—testicular cancer	0.00322	0.0197	CbGeAlD
Carvedilol—NDUFC2—seminal vesicle—testicular cancer	0.00281	0.0171	CbGeAlD
Carvedilol—HIF1A—gonad—testicular cancer	0.0024	0.0147	CbGeAlD
Carvedilol—GJA1—gonad—testicular cancer	0.00233	0.0142	CbGeAlD
Carvedilol—SELE—female gonad—testicular cancer	0.00221	0.0135	CbGeAlD
Carvedilol—VCAM1—female gonad—testicular cancer	0.00203	0.0124	CbGeAlD
Carvedilol—NDUFC2—gonad—testicular cancer	0.00203	0.0124	CbGeAlD
Carvedilol—SELE—testis—testicular cancer	0.00196	0.0119	CbGeAlD
Carvedilol—HIF1A—female gonad—testicular cancer	0.00195	0.0119	CbGeAlD
Carvedilol—GJA1—female gonad—testicular cancer	0.00189	0.0116	CbGeAlD
Carvedilol—VCAM1—testis—testicular cancer	0.0018	0.011	CbGeAlD
Carvedilol—ADRB3—female gonad—testicular cancer	0.00174	0.0106	CbGeAlD
Carvedilol—HIF1A—testis—testicular cancer	0.00173	0.0106	CbGeAlD
Carvedilol—GJA1—testis—testicular cancer	0.00168	0.0103	CbGeAlD
Carvedilol—NDUFC2—female gonad—testicular cancer	0.00165	0.0101	CbGeAlD
Carvedilol—VEGFA—female gonad—testicular cancer	0.0015	0.00913	CbGeAlD
Carvedilol—NDUFC2—testis—testicular cancer	0.00146	0.00892	CbGeAlD
Carvedilol—SELE—lymph node—testicular cancer	0.00142	0.00866	CbGeAlD
Carvedilol—VEGFA—testis—testicular cancer	0.00133	0.0081	CbGeAlD
Carvedilol—VCAM1—lymph node—testicular cancer	0.0013	0.00796	CbGeAlD
Carvedilol—HIF1A—lymph node—testicular cancer	0.00125	0.00766	CbGeAlD
Carvedilol—GJA1—lymph node—testicular cancer	0.00122	0.00743	CbGeAlD
Carvedilol—NDUFC2—lymph node—testicular cancer	0.00106	0.00647	CbGeAlD
Carvedilol—VEGFA—lymph node—testicular cancer	0.000961	0.00587	CbGeAlD
Carvedilol—KCNH2—seminal vesicle—testicular cancer	0.000923	0.00563	CbGeAlD
Carvedilol—ADRA2C—seminal vesicle—testicular cancer	0.00091	0.00556	CbGeAlD
Carvedilol—ADRA2A—seminal vesicle—testicular cancer	0.000726	0.00443	CbGeAlD
Carvedilol—CYP2E1—seminal vesicle—testicular cancer	0.000711	0.00434	CbGeAlD
Carvedilol—PTGS1—seminal vesicle—testicular cancer	0.000685	0.00418	CbGeAlD
Carvedilol—KCNH2—female gonad—testicular cancer	0.000542	0.00331	CbGeAlD
Carvedilol—ADRA2C—female gonad—testicular cancer	0.000535	0.00326	CbGeAlD
Carvedilol—ADRA2A—gonad—testicular cancer	0.000525	0.0032	CbGeAlD
Carvedilol—KCNH2—testis—testicular cancer	0.000481	0.00293	CbGeAlD
Carvedilol—ADRA2C—testis—testicular cancer	0.000474	0.00289	CbGeAlD
Carvedilol—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000472	0.0459	CbGpPWpGaD
Carvedilol—CYP1A1—female gonad—testicular cancer	0.000458	0.00279	CbGeAlD
Carvedilol—SELE—ATF-2 transcription factor network—MMP2—testicular cancer	0.000438	0.0426	CbGpPWpGaD
Carvedilol—ABCB1—embryo—testicular cancer	0.000431	0.00263	CbGeAlD
Carvedilol—ADRA2A—female gonad—testicular cancer	0.000427	0.0026	CbGeAlD
Carvedilol—ABCB1—seminal vesicle—testicular cancer	0.000405	0.00247	CbGeAlD
Carvedilol—PTGS1—female gonad—testicular cancer	0.000402	0.00245	CbGeAlD
Carvedilol—GJA1—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	0.000386	0.0375	CbGpPWpGaD
Carvedilol—ADRA2A—testis—testicular cancer	0.000378	0.00231	CbGeAlD
Carvedilol—CYP2E1—testis—testicular cancer	0.00037	0.00226	CbGeAlD
Carvedilol—VEGFA—NOTCH1 regulation of human endothelial cell calcification—FGFR3—testicular cancer	0.000367	0.0358	CbGpPWpGaD
Carvedilol—PTGS1—testis—testicular cancer	0.000357	0.00218	CbGeAlD
Carvedilol—KCNH2—lymph node—testicular cancer	0.000348	0.00213	CbGeAlD
Carvedilol—ADRA2C—lymph node—testicular cancer	0.000344	0.0021	CbGeAlD
Carvedilol—ADRB3—G alpha (s) signalling events—INSL3—testicular cancer	0.000343	0.0334	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000332	0.0323	CbGpPWpGaD
Carvedilol—CYP2D6—female gonad—testicular cancer	0.00033	0.00202	CbGeAlD
Carvedilol—CYP1A1—lymph node—testicular cancer	0.000294	0.0018	CbGeAlD
Carvedilol—CYP2D6—testis—testicular cancer	0.000293	0.00179	CbGeAlD
Carvedilol—ABCB1—gonad—testicular cancer	0.000292	0.00179	CbGeAlD
Carvedilol—ADRA2A—lymph node—testicular cancer	0.000274	0.00167	CbGeAlD
Carvedilol—PTGS1—lymph node—testicular cancer	0.000258	0.00158	CbGeAlD
Carvedilol—ABCB1—female gonad—testicular cancer	0.000238	0.00145	CbGeAlD
Carvedilol—HIF1A—AGE/RAGE pathway—MMP2—testicular cancer	0.000234	0.0228	CbGpPWpGaD
Carvedilol—VEGFA—Bladder Cancer—FGFR3—testicular cancer	0.000227	0.0221	CbGpPWpGaD
Carvedilol—KCNH2—Hematopoietic Stem Cell Differentiation—KITLG—testicular cancer	0.000226	0.022	CbGpPWpGaD
Carvedilol—VEGFA—Differentiation Pathway—KITLG—testicular cancer	0.000216	0.021	CbGpPWpGaD
Carvedilol—ABCB1—testis—testicular cancer	0.000211	0.00129	CbGeAlD
Carvedilol—ADRB1—G alpha (s) signalling events—INSL3—testicular cancer	0.000204	0.0198	CbGpPWpGaD
Carvedilol—ADRB2—G alpha (s) signalling events—INSL3—testicular cancer	0.000199	0.0194	CbGpPWpGaD
Carvedilol—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00017	0.0166	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—PRDM14—testicular cancer	0.000168	0.0163	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000164	0.0159	CbGpPWpGaD
Carvedilol—ABCB1—lymph node—testicular cancer	0.000153	0.000933	CbGeAlD
Carvedilol—VEGFA—Differentiation Pathway—KIT—testicular cancer	0.000147	0.0143	CbGpPWpGaD
Carvedilol—Pharyngitis—Methotrexate—testicular cancer	0.000146	0.000632	CcSEcCtD
Carvedilol—Urinary tract disorder—Methotrexate—testicular cancer	0.000145	0.000629	CcSEcCtD
Carvedilol—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000145	0.000629	CcSEcCtD
Carvedilol—Weight increased—Doxorubicin—testicular cancer	0.000144	0.000627	CcSEcCtD
Carvedilol—Urethral disorder—Methotrexate—testicular cancer	0.000144	0.000624	CcSEcCtD
Carvedilol—Weight decreased—Doxorubicin—testicular cancer	0.000144	0.000623	CcSEcCtD
Carvedilol—Sinusitis—Epirubicin—testicular cancer	0.000143	0.000623	CcSEcCtD
Carvedilol—Feeling abnormal—Etoposide—testicular cancer	0.000143	0.000622	CcSEcCtD
Carvedilol—Hyperglycaemia—Doxorubicin—testicular cancer	0.000143	0.000621	CcSEcCtD
Carvedilol—Nausea—Dactinomycin—testicular cancer	0.000143	0.00062	CcSEcCtD
Carvedilol—Pneumonia—Doxorubicin—testicular cancer	0.000142	0.000618	CcSEcCtD
Carvedilol—Gastrointestinal pain—Etoposide—testicular cancer	0.000142	0.000617	CcSEcCtD
Carvedilol—Visual impairment—Methotrexate—testicular cancer	0.000141	0.000613	CcSEcCtD
Carvedilol—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00014	0.000609	CcSEcCtD
Carvedilol—Vomiting—Ifosfamide—testicular cancer	0.00014	0.000608	CcSEcCtD
Carvedilol—Hypersensitivity—Cisplatin—testicular cancer	0.00014	0.000607	CcSEcCtD
Carvedilol—Bradycardia—Epirubicin—testicular cancer	0.00014	0.000606	CcSEcCtD
Carvedilol—Renal failure—Doxorubicin—testicular cancer	0.000139	0.000604	CcSEcCtD
Carvedilol—Rash—Ifosfamide—testicular cancer	0.000139	0.000603	CcSEcCtD
Carvedilol—HIF1A—Cellular responses to stress—H2AFZ—testicular cancer	0.000139	0.0135	CbGpPWpGaD
Carvedilol—Dermatitis—Ifosfamide—testicular cancer	0.000139	0.000602	CcSEcCtD
Carvedilol—Erythema multiforme—Methotrexate—testicular cancer	0.000139	0.000602	CcSEcCtD
Carvedilol—Urticaria—Etoposide—testicular cancer	0.000138	0.0006	CcSEcCtD
Carvedilol—Haemoglobin—Epirubicin—testicular cancer	0.000138	0.000599	CcSEcCtD
Carvedilol—Rhinitis—Epirubicin—testicular cancer	0.000138	0.000597	CcSEcCtD
Carvedilol—Body temperature increased—Etoposide—testicular cancer	0.000138	0.000597	CcSEcCtD
Carvedilol—Abdominal pain—Etoposide—testicular cancer	0.000138	0.000597	CcSEcCtD
Carvedilol—Urinary tract infection—Doxorubicin—testicular cancer	0.000138	0.000597	CcSEcCtD
Carvedilol—Haemorrhage—Epirubicin—testicular cancer	0.000137	0.000596	CcSEcCtD
Carvedilol—Tinnitus—Methotrexate—testicular cancer	0.000137	0.000593	CcSEcCtD
Carvedilol—Hypoaesthesia—Epirubicin—testicular cancer	0.000137	0.000593	CcSEcCtD
Carvedilol—Asthenia—Cisplatin—testicular cancer	0.000136	0.000591	CcSEcCtD
Carvedilol—Pharyngitis—Epirubicin—testicular cancer	0.000136	0.000591	CcSEcCtD
Carvedilol—Urinary tract disorder—Epirubicin—testicular cancer	0.000136	0.000588	CcSEcCtD
Carvedilol—Oedema peripheral—Epirubicin—testicular cancer	0.000135	0.000587	CcSEcCtD
Carvedilol—Haematuria—Doxorubicin—testicular cancer	0.000135	0.000585	CcSEcCtD
Carvedilol—Urethral disorder—Epirubicin—testicular cancer	0.000135	0.000584	CcSEcCtD
Carvedilol—Angiopathy—Methotrexate—testicular cancer	0.000133	0.000578	CcSEcCtD
Carvedilol—Sinusitis—Doxorubicin—testicular cancer	0.000133	0.000576	CcSEcCtD
Carvedilol—Immune system disorder—Methotrexate—testicular cancer	0.000132	0.000575	CcSEcCtD
Carvedilol—Visual impairment—Epirubicin—testicular cancer	0.000132	0.000574	CcSEcCtD
Carvedilol—Mediastinal disorder—Methotrexate—testicular cancer	0.000132	0.000574	CcSEcCtD
Carvedilol—Nausea—Ifosfamide—testicular cancer	0.000131	0.000568	CcSEcCtD
Carvedilol—Diarrhoea—Cisplatin—testicular cancer	0.00013	0.000564	CcSEcCtD
Carvedilol—Erythema multiforme—Epirubicin—testicular cancer	0.00013	0.000563	CcSEcCtD
Carvedilol—Alopecia—Methotrexate—testicular cancer	0.00013	0.000562	CcSEcCtD
Carvedilol—Bradycardia—Doxorubicin—testicular cancer	0.000129	0.000561	CcSEcCtD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000128	0.0125	CbGpPWpGaD
Carvedilol—Hypersensitivity—Etoposide—testicular cancer	0.000128	0.000556	CcSEcCtD
Carvedilol—Tinnitus—Epirubicin—testicular cancer	0.000128	0.000555	CcSEcCtD
Carvedilol—Malnutrition—Methotrexate—testicular cancer	0.000128	0.000554	CcSEcCtD
Carvedilol—Haemoglobin—Doxorubicin—testicular cancer	0.000128	0.000554	CcSEcCtD
Carvedilol—Rhinitis—Doxorubicin—testicular cancer	0.000127	0.000553	CcSEcCtD
Carvedilol—VEGFA—Endochondral Ossification—FGFR3—testicular cancer	0.000127	0.0124	CbGpPWpGaD
Carvedilol—Haemorrhage—Doxorubicin—testicular cancer	0.000127	0.000551	CcSEcCtD
Carvedilol—Hypoaesthesia—Doxorubicin—testicular cancer	0.000126	0.000548	CcSEcCtD
Carvedilol—Pharyngitis—Doxorubicin—testicular cancer	0.000126	0.000547	CcSEcCtD
Carvedilol—Urinary tract disorder—Doxorubicin—testicular cancer	0.000125	0.000544	CcSEcCtD
Carvedilol—Oedema peripheral—Doxorubicin—testicular cancer	0.000125	0.000543	CcSEcCtD
Carvedilol—Asthenia—Etoposide—testicular cancer	0.000125	0.000542	CcSEcCtD
Carvedilol—ADRB3—GPCR ligand binding—INSL3—testicular cancer	0.000125	0.0121	CbGpPWpGaD
Carvedilol—Angiopathy—Epirubicin—testicular cancer	0.000125	0.00054	CcSEcCtD
Carvedilol—Urethral disorder—Doxorubicin—testicular cancer	0.000125	0.00054	CcSEcCtD
Carvedilol—Immune system disorder—Epirubicin—testicular cancer	0.000124	0.000538	CcSEcCtD
Carvedilol—Mediastinal disorder—Epirubicin—testicular cancer	0.000124	0.000537	CcSEcCtD
Carvedilol—Back pain—Methotrexate—testicular cancer	0.000124	0.000536	CcSEcCtD
Carvedilol—Pruritus—Etoposide—testicular cancer	0.000123	0.000534	CcSEcCtD
Carvedilol—VCAM1—Adaptive Immune System—BCL10—testicular cancer	0.000123	0.0119	CbGpPWpGaD
Carvedilol—Visual impairment—Doxorubicin—testicular cancer	0.000122	0.000531	CcSEcCtD
Carvedilol—Alopecia—Epirubicin—testicular cancer	0.000121	0.000526	CcSEcCtD
Carvedilol—Vomiting—Cisplatin—testicular cancer	0.000121	0.000524	CcSEcCtD
Carvedilol—Vision blurred—Methotrexate—testicular cancer	0.00012	0.000522	CcSEcCtD
Carvedilol—CYP1A1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00012	0.0117	CbGpPWpGaD
Carvedilol—Erythema multiforme—Doxorubicin—testicular cancer	0.00012	0.000521	CcSEcCtD
Carvedilol—Rash—Cisplatin—testicular cancer	0.00012	0.00052	CcSEcCtD
Carvedilol—Dermatitis—Cisplatin—testicular cancer	0.00012	0.000519	CcSEcCtD
Carvedilol—Malnutrition—Epirubicin—testicular cancer	0.000119	0.000519	CcSEcCtD
Carvedilol—Diarrhoea—Etoposide—testicular cancer	0.000119	0.000517	CcSEcCtD
Carvedilol—Ill-defined disorder—Methotrexate—testicular cancer	0.000118	0.000514	CcSEcCtD
Carvedilol—Tinnitus—Doxorubicin—testicular cancer	0.000118	0.000514	CcSEcCtD
Carvedilol—Anaemia—Methotrexate—testicular cancer	0.000118	0.000512	CcSEcCtD
Carvedilol—Flatulence—Epirubicin—testicular cancer	0.000118	0.000511	CcSEcCtD
Carvedilol—Tension—Epirubicin—testicular cancer	0.000117	0.000509	CcSEcCtD
Carvedilol—Nervousness—Epirubicin—testicular cancer	0.000116	0.000504	CcSEcCtD
Carvedilol—Back pain—Epirubicin—testicular cancer	0.000116	0.000502	CcSEcCtD
Carvedilol—Angiopathy—Doxorubicin—testicular cancer	0.000115	0.0005	CcSEcCtD
Carvedilol—Malaise—Methotrexate—testicular cancer	0.000115	0.0005	CcSEcCtD
Carvedilol—Dizziness—Etoposide—testicular cancer	0.000115	0.000499	CcSEcCtD
Carvedilol—Muscle spasms—Epirubicin—testicular cancer	0.000115	0.000499	CcSEcCtD
Carvedilol—Immune system disorder—Doxorubicin—testicular cancer	0.000115	0.000498	CcSEcCtD
Carvedilol—Vertigo—Methotrexate—testicular cancer	0.000115	0.000498	CcSEcCtD
Carvedilol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000114	0.000497	CcSEcCtD
Carvedilol—Leukopenia—Methotrexate—testicular cancer	0.000114	0.000496	CcSEcCtD
Carvedilol—Nausea—Cisplatin—testicular cancer	0.000113	0.00049	CcSEcCtD
Carvedilol—Vision blurred—Epirubicin—testicular cancer	0.000113	0.000489	CcSEcCtD
Carvedilol—Alopecia—Doxorubicin—testicular cancer	0.000112	0.000487	CcSEcCtD
Carvedilol—Cough—Methotrexate—testicular cancer	0.000111	0.000484	CcSEcCtD
Carvedilol—Ill-defined disorder—Epirubicin—testicular cancer	0.000111	0.000481	CcSEcCtD
Carvedilol—Convulsion—Methotrexate—testicular cancer	0.000111	0.00048	CcSEcCtD
Carvedilol—Vomiting—Etoposide—testicular cancer	0.000111	0.00048	CcSEcCtD
Carvedilol—Malnutrition—Doxorubicin—testicular cancer	0.000111	0.00048	CcSEcCtD
Carvedilol—Anaemia—Epirubicin—testicular cancer	0.00011	0.000479	CcSEcCtD
Carvedilol—Rash—Etoposide—testicular cancer	0.00011	0.000476	CcSEcCtD
Carvedilol—Dermatitis—Etoposide—testicular cancer	0.00011	0.000476	CcSEcCtD
Carvedilol—Headache—Etoposide—testicular cancer	0.000109	0.000473	CcSEcCtD
Carvedilol—Flatulence—Doxorubicin—testicular cancer	0.000109	0.000473	CcSEcCtD
Carvedilol—Myalgia—Methotrexate—testicular cancer	0.000109	0.000472	CcSEcCtD
Carvedilol—Arthralgia—Methotrexate—testicular cancer	0.000109	0.000472	CcSEcCtD
Carvedilol—Chest pain—Methotrexate—testicular cancer	0.000109	0.000472	CcSEcCtD
Carvedilol—Tension—Doxorubicin—testicular cancer	0.000108	0.000471	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000108	0.000468	CcSEcCtD
Carvedilol—Malaise—Epirubicin—testicular cancer	0.000108	0.000468	CcSEcCtD
Carvedilol—Discomfort—Methotrexate—testicular cancer	0.000107	0.000466	CcSEcCtD
Carvedilol—Nervousness—Doxorubicin—testicular cancer	0.000107	0.000466	CcSEcCtD
Carvedilol—Vertigo—Epirubicin—testicular cancer	0.000107	0.000466	CcSEcCtD
Carvedilol—Syncope—Epirubicin—testicular cancer	0.000107	0.000465	CcSEcCtD
Carvedilol—Leukopenia—Epirubicin—testicular cancer	0.000107	0.000464	CcSEcCtD
Carvedilol—Back pain—Doxorubicin—testicular cancer	0.000107	0.000464	CcSEcCtD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000107	0.0104	CbGpPWpGaD
Carvedilol—Muscle spasms—Doxorubicin—testicular cancer	0.000106	0.000461	CcSEcCtD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000106	0.0103	CbGpPWpGaD
Carvedilol—Palpitations—Epirubicin—testicular cancer	0.000106	0.000458	CcSEcCtD
Carvedilol—Confusional state—Methotrexate—testicular cancer	0.000105	0.000456	CcSEcCtD
Carvedilol—Loss of consciousness—Epirubicin—testicular cancer	0.000105	0.000456	CcSEcCtD
Carvedilol—Cough—Epirubicin—testicular cancer	0.000104	0.000452	CcSEcCtD
Carvedilol—Anaphylactic shock—Methotrexate—testicular cancer	0.000104	0.000452	CcSEcCtD
Carvedilol—Vision blurred—Doxorubicin—testicular cancer	0.000104	0.000452	CcSEcCtD
Carvedilol—Convulsion—Epirubicin—testicular cancer	0.000104	0.000449	CcSEcCtD
Carvedilol—Infection—Methotrexate—testicular cancer	0.000104	0.000449	CcSEcCtD
Carvedilol—Nausea—Etoposide—testicular cancer	0.000103	0.000448	CcSEcCtD
Carvedilol—Hypertension—Epirubicin—testicular cancer	0.000103	0.000448	CcSEcCtD
Carvedilol—Ill-defined disorder—Doxorubicin—testicular cancer	0.000103	0.000445	CcSEcCtD
Carvedilol—Anaemia—Doxorubicin—testicular cancer	0.000102	0.000443	CcSEcCtD
Carvedilol—Thrombocytopenia—Methotrexate—testicular cancer	0.000102	0.000443	CcSEcCtD
Carvedilol—Myalgia—Epirubicin—testicular cancer	0.000102	0.000441	CcSEcCtD
Carvedilol—Chest pain—Epirubicin—testicular cancer	0.000102	0.000441	CcSEcCtD
Carvedilol—Arthralgia—Epirubicin—testicular cancer	0.000102	0.000441	CcSEcCtD
Carvedilol—Skin disorder—Methotrexate—testicular cancer	0.000101	0.000439	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000101	0.000438	CcSEcCtD
Carvedilol—Hyperhidrosis—Methotrexate—testicular cancer	0.000101	0.000437	CcSEcCtD
Carvedilol—Discomfort—Epirubicin—testicular cancer	0.000101	0.000436	CcSEcCtD
Carvedilol—Malaise—Doxorubicin—testicular cancer	9.97e-05	0.000433	CcSEcCtD
Carvedilol—Dry mouth—Epirubicin—testicular cancer	9.95e-05	0.000432	CcSEcCtD
Carvedilol—Vertigo—Doxorubicin—testicular cancer	9.93e-05	0.000431	CcSEcCtD
Carvedilol—Anorexia—Methotrexate—testicular cancer	9.93e-05	0.000431	CcSEcCtD
Carvedilol—Syncope—Doxorubicin—testicular cancer	9.92e-05	0.00043	CcSEcCtD
Carvedilol—Leukopenia—Doxorubicin—testicular cancer	9.9e-05	0.000429	CcSEcCtD
Carvedilol—Confusional state—Epirubicin—testicular cancer	9.83e-05	0.000427	CcSEcCtD
Carvedilol—Palpitations—Doxorubicin—testicular cancer	9.77e-05	0.000424	CcSEcCtD
Carvedilol—Oedema—Epirubicin—testicular cancer	9.75e-05	0.000423	CcSEcCtD
Carvedilol—Anaphylactic shock—Epirubicin—testicular cancer	9.75e-05	0.000423	CcSEcCtD
Carvedilol—Hypotension—Methotrexate—testicular cancer	9.74e-05	0.000423	CcSEcCtD
Carvedilol—Loss of consciousness—Doxorubicin—testicular cancer	9.72e-05	0.000422	CcSEcCtD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.71e-05	0.00945	CbGpPWpGaD
Carvedilol—Infection—Epirubicin—testicular cancer	9.69e-05	0.00042	CcSEcCtD
Carvedilol—Cough—Doxorubicin—testicular cancer	9.65e-05	0.000419	CcSEcCtD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.62e-05	0.00936	CbGpPWpGaD
Carvedilol—Shock—Epirubicin—testicular cancer	9.59e-05	0.000416	CcSEcCtD
Carvedilol—Convulsion—Doxorubicin—testicular cancer	9.58e-05	0.000416	CcSEcCtD
Carvedilol—Thrombocytopenia—Epirubicin—testicular cancer	9.55e-05	0.000414	CcSEcCtD
Carvedilol—Hypertension—Doxorubicin—testicular cancer	9.55e-05	0.000414	CcSEcCtD
Carvedilol—Tachycardia—Epirubicin—testicular cancer	9.52e-05	0.000413	CcSEcCtD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.5e-05	0.00924	CbGpPWpGaD
Carvedilol—Musculoskeletal discomfort—Methotrexate—testicular cancer	9.49e-05	0.000412	CcSEcCtD
Carvedilol—Skin disorder—Epirubicin—testicular cancer	9.47e-05	0.000411	CcSEcCtD
Carvedilol—ADRA1B—AMPK Signaling—STK11—testicular cancer	9.44e-05	0.00918	CbGpPWpGaD
Carvedilol—Hyperhidrosis—Epirubicin—testicular cancer	9.43e-05	0.000409	CcSEcCtD
Carvedilol—Insomnia—Methotrexate—testicular cancer	9.43e-05	0.000409	CcSEcCtD
Carvedilol—Arthralgia—Doxorubicin—testicular cancer	9.41e-05	0.000408	CcSEcCtD
Carvedilol—Chest pain—Doxorubicin—testicular cancer	9.41e-05	0.000408	CcSEcCtD
Carvedilol—Myalgia—Doxorubicin—testicular cancer	9.41e-05	0.000408	CcSEcCtD
Carvedilol—Paraesthesia—Methotrexate—testicular cancer	9.36e-05	0.000406	CcSEcCtD
Carvedilol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	9.35e-05	0.000406	CcSEcCtD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—STK11—testicular cancer	9.31e-05	0.00906	CbGpPWpGaD
Carvedilol—Discomfort—Doxorubicin—testicular cancer	9.3e-05	0.000404	CcSEcCtD
Carvedilol—Anorexia—Epirubicin—testicular cancer	9.3e-05	0.000403	CcSEcCtD
Carvedilol—Dyspnoea—Methotrexate—testicular cancer	9.29e-05	0.000403	CcSEcCtD
Carvedilol—Somnolence—Methotrexate—testicular cancer	9.26e-05	0.000402	CcSEcCtD
Carvedilol—Dry mouth—Doxorubicin—testicular cancer	9.21e-05	0.000399	CcSEcCtD
Carvedilol—Dyspepsia—Methotrexate—testicular cancer	9.17e-05	0.000398	CcSEcCtD
Carvedilol—Hypotension—Epirubicin—testicular cancer	9.11e-05	0.000395	CcSEcCtD
Carvedilol—Confusional state—Doxorubicin—testicular cancer	9.1e-05	0.000395	CcSEcCtD
Carvedilol—Decreased appetite—Methotrexate—testicular cancer	9.06e-05	0.000393	CcSEcCtD
Carvedilol—Oedema—Doxorubicin—testicular cancer	9.02e-05	0.000392	CcSEcCtD
Carvedilol—Anaphylactic shock—Doxorubicin—testicular cancer	9.02e-05	0.000392	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Methotrexate—testicular cancer	9e-05	0.00039	CcSEcCtD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	8.99e-05	0.00875	CbGpPWpGaD
Carvedilol—Fatigue—Methotrexate—testicular cancer	8.98e-05	0.00039	CcSEcCtD
Carvedilol—Infection—Doxorubicin—testicular cancer	8.96e-05	0.000389	CcSEcCtD
Carvedilol—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	8.96e-05	0.00872	CbGpPWpGaD
Carvedilol—Pain—Methotrexate—testicular cancer	8.91e-05	0.000387	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.89e-05	0.000386	CcSEcCtD
Carvedilol—Shock—Doxorubicin—testicular cancer	8.88e-05	0.000385	CcSEcCtD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	8.85e-05	0.00861	CbGpPWpGaD
Carvedilol—Thrombocytopenia—Doxorubicin—testicular cancer	8.83e-05	0.000383	CcSEcCtD
Carvedilol—Insomnia—Epirubicin—testicular cancer	8.82e-05	0.000383	CcSEcCtD
Carvedilol—Tachycardia—Doxorubicin—testicular cancer	8.81e-05	0.000382	CcSEcCtD
Carvedilol—Skin disorder—Doxorubicin—testicular cancer	8.76e-05	0.00038	CcSEcCtD
Carvedilol—Paraesthesia—Epirubicin—testicular cancer	8.76e-05	0.00038	CcSEcCtD
Carvedilol—HIF1A—Signaling Pathways—INSL3—testicular cancer	8.74e-05	0.0085	CbGpPWpGaD
Carvedilol—Hyperhidrosis—Doxorubicin—testicular cancer	8.72e-05	0.000379	CcSEcCtD
Carvedilol—VCAM1—Extracellular matrix organization—MMP2—testicular cancer	8.71e-05	0.00848	CbGpPWpGaD
Carvedilol—Dyspnoea—Epirubicin—testicular cancer	8.69e-05	0.000377	CcSEcCtD
Carvedilol—Somnolence—Epirubicin—testicular cancer	8.67e-05	0.000376	CcSEcCtD
Carvedilol—Anorexia—Doxorubicin—testicular cancer	8.6e-05	0.000373	CcSEcCtD
Carvedilol—Feeling abnormal—Methotrexate—testicular cancer	8.59e-05	0.000373	CcSEcCtD
Carvedilol—Dyspepsia—Epirubicin—testicular cancer	8.58e-05	0.000373	CcSEcCtD
Carvedilol—Gastrointestinal pain—Methotrexate—testicular cancer	8.52e-05	0.00037	CcSEcCtD
Carvedilol—Decreased appetite—Epirubicin—testicular cancer	8.48e-05	0.000368	CcSEcCtD
Carvedilol—Hypotension—Doxorubicin—testicular cancer	8.43e-05	0.000366	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Epirubicin—testicular cancer	8.42e-05	0.000365	CcSEcCtD
Carvedilol—Fatigue—Epirubicin—testicular cancer	8.41e-05	0.000365	CcSEcCtD
Carvedilol—ADRA1A—AMPK Signaling—STK11—testicular cancer	8.38e-05	0.00816	CbGpPWpGaD
Carvedilol—Pain—Epirubicin—testicular cancer	8.34e-05	0.000362	CcSEcCtD
Carvedilol—Constipation—Epirubicin—testicular cancer	8.34e-05	0.000362	CcSEcCtD
Carvedilol—Urticaria—Methotrexate—testicular cancer	8.28e-05	0.000359	CcSEcCtD
Carvedilol—Abdominal pain—Methotrexate—testicular cancer	8.24e-05	0.000357	CcSEcCtD
Carvedilol—Body temperature increased—Methotrexate—testicular cancer	8.24e-05	0.000357	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	8.22e-05	0.000357	CcSEcCtD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	8.19e-05	0.00797	CbGpPWpGaD
Carvedilol—Insomnia—Doxorubicin—testicular cancer	8.16e-05	0.000354	CcSEcCtD
Carvedilol—ADRA1D—GPCR ligand binding—INSL3—testicular cancer	8.12e-05	0.0079	CbGpPWpGaD
Carvedilol—Paraesthesia—Doxorubicin—testicular cancer	8.1e-05	0.000352	CcSEcCtD
Carvedilol—Dyspnoea—Doxorubicin—testicular cancer	8.04e-05	0.000349	CcSEcCtD
Carvedilol—Feeling abnormal—Epirubicin—testicular cancer	8.04e-05	0.000349	CcSEcCtD
Carvedilol—Somnolence—Doxorubicin—testicular cancer	8.02e-05	0.000348	CcSEcCtD
Carvedilol—Gastrointestinal pain—Epirubicin—testicular cancer	7.97e-05	0.000346	CcSEcCtD
Carvedilol—Dyspepsia—Doxorubicin—testicular cancer	7.94e-05	0.000345	CcSEcCtD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.86e-05	0.00765	CbGpPWpGaD
Carvedilol—Decreased appetite—Doxorubicin—testicular cancer	7.84e-05	0.00034	CcSEcCtD
Carvedilol—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.79e-05	0.000338	CcSEcCtD
Carvedilol—Fatigue—Doxorubicin—testicular cancer	7.78e-05	0.000338	CcSEcCtD
Carvedilol—Urticaria—Epirubicin—testicular cancer	7.75e-05	0.000336	CcSEcCtD
Carvedilol—Pain—Doxorubicin—testicular cancer	7.72e-05	0.000335	CcSEcCtD
Carvedilol—Constipation—Doxorubicin—testicular cancer	7.72e-05	0.000335	CcSEcCtD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	7.72e-05	0.00751	CbGpPWpGaD
Carvedilol—Body temperature increased—Epirubicin—testicular cancer	7.71e-05	0.000335	CcSEcCtD
Carvedilol—Abdominal pain—Epirubicin—testicular cancer	7.71e-05	0.000335	CcSEcCtD
Carvedilol—Hypersensitivity—Methotrexate—testicular cancer	7.68e-05	0.000333	CcSEcCtD
Carvedilol—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	7.66e-05	0.00745	CbGpPWpGaD
Carvedilol—VEGFA—EPH-Ephrin signaling—MMP2—testicular cancer	7.61e-05	0.00741	CbGpPWpGaD
Carvedilol—Asthenia—Methotrexate—testicular cancer	7.48e-05	0.000324	CcSEcCtD
Carvedilol—VCAM1—Immune System—BCL10—testicular cancer	7.45e-05	0.00724	CbGpPWpGaD
Carvedilol—Feeling abnormal—Doxorubicin—testicular cancer	7.44e-05	0.000323	CcSEcCtD
Carvedilol—VCAM1—Adaptive Immune System—KITLG—testicular cancer	7.4e-05	0.0072	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—INSL3—testicular cancer	7.4e-05	0.0072	CbGpPWpGaD
Carvedilol—Gastrointestinal pain—Doxorubicin—testicular cancer	7.38e-05	0.00032	CcSEcCtD
Carvedilol—Pruritus—Methotrexate—testicular cancer	7.37e-05	0.00032	CcSEcCtD
Carvedilol—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	7.33e-05	0.00713	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.3e-05	0.0071	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—INSL3—testicular cancer	7.23e-05	0.00704	CbGpPWpGaD
Carvedilol—Hypersensitivity—Epirubicin—testicular cancer	7.19e-05	0.000312	CcSEcCtD
Carvedilol—Urticaria—Doxorubicin—testicular cancer	7.17e-05	0.000311	CcSEcCtD
Carvedilol—Abdominal pain—Doxorubicin—testicular cancer	7.13e-05	0.00031	CcSEcCtD
Carvedilol—Body temperature increased—Doxorubicin—testicular cancer	7.13e-05	0.00031	CcSEcCtD
Carvedilol—Diarrhoea—Methotrexate—testicular cancer	7.13e-05	0.000309	CcSEcCtD
Carvedilol—ADRB3—GPCR downstream signaling—INSL3—testicular cancer	7.04e-05	0.00685	CbGpPWpGaD
Carvedilol—Asthenia—Epirubicin—testicular cancer	7e-05	0.000304	CcSEcCtD
Carvedilol—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	6.91e-05	0.00672	CbGpPWpGaD
Carvedilol—Pruritus—Epirubicin—testicular cancer	6.9e-05	0.000299	CcSEcCtD
Carvedilol—Dizziness—Methotrexate—testicular cancer	6.89e-05	0.000299	CcSEcCtD
Carvedilol—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	6.85e-05	0.00666	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	6.74e-05	0.00655	CbGpPWpGaD
Carvedilol—Diarrhoea—Epirubicin—testicular cancer	6.67e-05	0.00029	CcSEcCtD
Carvedilol—Hypersensitivity—Doxorubicin—testicular cancer	6.65e-05	0.000289	CcSEcCtD
Carvedilol—Vomiting—Methotrexate—testicular cancer	6.63e-05	0.000288	CcSEcCtD
Carvedilol—Rash—Methotrexate—testicular cancer	6.57e-05	0.000285	CcSEcCtD
Carvedilol—Dermatitis—Methotrexate—testicular cancer	6.56e-05	0.000285	CcSEcCtD
Carvedilol—Headache—Methotrexate—testicular cancer	6.53e-05	0.000283	CcSEcCtD
Carvedilol—Asthenia—Doxorubicin—testicular cancer	6.47e-05	0.000281	CcSEcCtD
Carvedilol—Dizziness—Epirubicin—testicular cancer	6.45e-05	0.00028	CcSEcCtD
Carvedilol—ADRB3—Signaling by GPCR—INSL3—testicular cancer	6.39e-05	0.00622	CbGpPWpGaD
Carvedilol—Pruritus—Doxorubicin—testicular cancer	6.38e-05	0.000277	CcSEcCtD
Carvedilol—PTGS1—Biological oxidations—HPGDS—testicular cancer	6.34e-05	0.00617	CbGpPWpGaD
Carvedilol—Vomiting—Epirubicin—testicular cancer	6.2e-05	0.000269	CcSEcCtD
Carvedilol—Nausea—Methotrexate—testicular cancer	6.19e-05	0.000269	CcSEcCtD
Carvedilol—Diarrhoea—Doxorubicin—testicular cancer	6.17e-05	0.000268	CcSEcCtD
Carvedilol—Rash—Epirubicin—testicular cancer	6.15e-05	0.000267	CcSEcCtD
Carvedilol—Dermatitis—Epirubicin—testicular cancer	6.14e-05	0.000267	CcSEcCtD
Carvedilol—Headache—Epirubicin—testicular cancer	6.11e-05	0.000265	CcSEcCtD
Carvedilol—VEGFA—Cellular responses to stress—H2AFZ—testicular cancer	5.99e-05	0.00583	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	5.98e-05	0.00582	CbGpPWpGaD
Carvedilol—Dizziness—Doxorubicin—testicular cancer	5.97e-05	0.000259	CcSEcCtD
Carvedilol—NDUFC2—Metabolism—HPGDS—testicular cancer	5.94e-05	0.00578	CbGpPWpGaD
Carvedilol—Nausea—Epirubicin—testicular cancer	5.79e-05	0.000251	CcSEcCtD
Carvedilol—Vomiting—Doxorubicin—testicular cancer	5.74e-05	0.000249	CcSEcCtD
Carvedilol—Rash—Doxorubicin—testicular cancer	5.69e-05	0.000247	CcSEcCtD
Carvedilol—Dermatitis—Doxorubicin—testicular cancer	5.68e-05	0.000247	CcSEcCtD
Carvedilol—Headache—Doxorubicin—testicular cancer	5.65e-05	0.000245	CcSEcCtD
Carvedilol—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	5.61e-05	0.00546	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	5.61e-05	0.00546	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	5.56e-05	0.00541	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—FGFR3—testicular cancer	5.5e-05	0.00535	CbGpPWpGaD
Carvedilol—Nausea—Doxorubicin—testicular cancer	5.36e-05	0.000233	CcSEcCtD
Carvedilol—VCAM1—Adaptive Immune System—KIT—testicular cancer	5.05e-05	0.00491	CbGpPWpGaD
Carvedilol—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	4.87e-05	0.00474	CbGpPWpGaD
Carvedilol—CYP2E1—Biological oxidations—HPGDS—testicular cancer	4.74e-05	0.00461	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—INSL3—testicular cancer	4.59e-05	0.00446	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KITLG—testicular cancer	4.49e-05	0.00437	CbGpPWpGaD
Carvedilol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	4.47e-05	0.00435	CbGpPWpGaD
Carvedilol—CYP1A1—Biological oxidations—HPGDS—testicular cancer	4.47e-05	0.00435	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—STK11—testicular cancer	4.31e-05	0.0042	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	4.18e-05	0.00407	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—INSL3—testicular cancer	4.17e-05	0.00405	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	4.14e-05	0.00403	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—INSL3—testicular cancer	4.09e-05	0.00398	CbGpPWpGaD
Carvedilol—HIF1A—Disease—H2AFZ—testicular cancer	3.99e-05	0.00388	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	3.87e-05	0.00376	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	3.81e-05	0.0037	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—INSL3—testicular cancer	3.8e-05	0.00369	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—INSL3—testicular cancer	3.78e-05	0.00368	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—INSL3—testicular cancer	3.77e-05	0.00367	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	3.76e-05	0.00366	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—INSL3—testicular cancer	3.71e-05	0.00361	CbGpPWpGaD
Carvedilol—HIF1A—Disease—KITLG—testicular cancer	3.67e-05	0.00357	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.59e-05	0.00349	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	3.51e-05	0.00342	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	3.46e-05	0.00336	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	3.38e-05	0.00329	CbGpPWpGaD
Carvedilol—CYP2D6—Biological oxidations—HPGDS—testicular cancer	3.36e-05	0.00327	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—FGFR3—testicular cancer	3.34e-05	0.00325	CbGpPWpGaD
Carvedilol—CYP2C9—Biological oxidations—HPGDS—testicular cancer	3.34e-05	0.00325	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.28e-05	0.00319	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	3.14e-05	0.00306	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	3.07e-05	0.00299	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KIT—testicular cancer	3.06e-05	0.00298	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	2.85e-05	0.00278	CbGpPWpGaD
Carvedilol—CYP1A2—Biological oxidations—HPGDS—testicular cancer	2.85e-05	0.00277	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—MMP2—testicular cancer	2.83e-05	0.00275	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—H2AFZ—testicular cancer	2.8e-05	0.00272	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—STK11—testicular cancer	2.78e-05	0.0027	CbGpPWpGaD
Carvedilol—HIF1A—Disease—FGFR3—testicular cancer	2.73e-05	0.00266	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KITLG—testicular cancer	2.57e-05	0.0025	CbGpPWpGaD
Carvedilol—HIF1A—Disease—KIT—testicular cancer	2.51e-05	0.00244	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—INSL3—testicular cancer	2.46e-05	0.00239	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.44e-05	0.00237	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.39e-05	0.00232	CbGpPWpGaD
Carvedilol—XDH—Metabolism—HPGDS—testicular cancer	2.32e-05	0.00225	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—INSL3—testicular cancer	2.24e-05	0.00218	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—INSL3—testicular cancer	2.22e-05	0.00216	CbGpPWpGaD
Carvedilol—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.2e-05	0.00214	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—INSL3—testicular cancer	2.19e-05	0.00213	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—INSL3—testicular cancer	2.08e-05	0.00202	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—INSL3—testicular cancer	2.04e-05	0.00199	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP2—testicular cancer	2.02e-05	0.00196	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—FGFR3—testicular cancer	1.91e-05	0.00186	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—INSL3—testicular cancer	1.81e-05	0.00177	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KIT—testicular cancer	1.76e-05	0.00171	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.72e-05	0.00167	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—INSL3—testicular cancer	1.69e-05	0.00164	CbGpPWpGaD
Carvedilol—XDH—Metabolism—STK11—testicular cancer	1.68e-05	0.00164	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.28e-05	0.00125	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—H2AFZ—testicular cancer	1.21e-05	0.00118	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—H2AFZ—testicular cancer	1.21e-05	0.00117	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—STK11—testicular cancer	1.2e-05	0.00117	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STK11—testicular cancer	1.2e-05	0.00117	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KITLG—testicular cancer	1.11e-05	0.00108	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KITLG—testicular cancer	1.11e-05	0.00108	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.09e-05	0.00106	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—HPGDS—testicular cancer	1.09e-05	0.00106	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—HPGDS—testicular cancer	1.09e-05	0.00106	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—HPGDS—testicular cancer	8.83e-06	0.000859	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—FGFR3—testicular cancer	8.27e-06	0.000804	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—FGFR3—testicular cancer	8.25e-06	0.000803	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—HPGDS—testicular cancer	8.11e-06	0.000789	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—STK11—testicular cancer	7.9e-06	0.000769	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—STK11—testicular cancer	7.88e-06	0.000767	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—H2AFZ—testicular cancer	7.88e-06	0.000766	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STK11—testicular cancer	7.83e-06	0.000762	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—HPGDS—testicular cancer	7.64e-06	0.000744	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KIT—testicular cancer	7.59e-06	0.000739	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KIT—testicular cancer	7.57e-06	0.000737	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KITLG—testicular cancer	7.25e-06	0.000705	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	7.18e-06	0.000698	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STK11—testicular cancer	7.14e-06	0.000694	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	7.11e-06	0.000692	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STK11—testicular cancer	7.07e-06	0.000688	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—H2AFZ—testicular cancer	7.02e-06	0.000683	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STK11—testicular cancer	6.98e-06	0.000679	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	6.64e-06	0.000646	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STK11—testicular cancer	6.6e-06	0.000643	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KITLG—testicular cancer	6.6e-06	0.000642	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KITLG—testicular cancer	6.54e-06	0.000637	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	6.54e-06	0.000636	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STK11—testicular cancer	6.5e-06	0.000632	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KITLG—testicular cancer	6.46e-06	0.000628	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—STK11—testicular cancer	6.42e-06	0.000624	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KITLG—testicular cancer	6.11e-06	0.000595	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—HPGDS—testicular cancer	6.11e-06	0.000594	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KITLG—testicular cancer	6.01e-06	0.000585	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—STK11—testicular cancer	5.89e-06	0.000573	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	5.81e-06	0.000565	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STK11—testicular cancer	5.77e-06	0.000562	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—HPGDS—testicular cancer	5.75e-06	0.00056	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—HPGDS—testicular cancer	5.7e-06	0.000555	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—STK11—testicular cancer	5.55e-06	0.00054	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	5.4e-06	0.000525	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—FGFR3—testicular cancer	5.39e-06	0.000524	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STK11—testicular cancer	5.36e-06	0.000522	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KITLG—testicular cancer	5.34e-06	0.00052	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KITLG—testicular cancer	4.96e-06	0.000483	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KIT—testicular cancer	4.94e-06	0.000481	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—FGFR3—testicular cancer	4.91e-06	0.000477	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—HPGDS—testicular cancer	4.87e-06	0.000474	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	4.86e-06	0.000473	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—FGFR3—testicular cancer	4.8e-06	0.000467	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	4.54e-06	0.000442	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KIT—testicular cancer	4.51e-06	0.000438	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	4.47e-06	0.000435	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KIT—testicular cancer	4.46e-06	0.000434	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—STK11—testicular cancer	4.44e-06	0.000432	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KIT—testicular cancer	4.41e-06	0.000429	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—STK11—testicular cancer	4.18e-06	0.000407	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KIT—testicular cancer	4.17e-06	0.000406	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—STK11—testicular cancer	4.14e-06	0.000403	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KIT—testicular cancer	4.1e-06	0.000399	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	3.97e-06	0.000386	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—HPGDS—testicular cancer	3.76e-06	0.000366	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	3.69e-06	0.000359	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KIT—testicular cancer	3.65e-06	0.000355	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—STK11—testicular cancer	3.54e-06	0.000345	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KIT—testicular cancer	3.39e-06	0.00033	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—STK11—testicular cancer	2.73e-06	0.000266	CbGpPWpGaD
